Can Enanta Pharmaceuticals Inc (ENTA)’s Tomorrow Be Different? The Stock Increases Again

September 17, 2017 - By reb123z

Investors sentiment decreased to 1.47 in 2016 Q4. Its down 0.06, from 1.53 in 2016Q3. It dived, as 13 investors sold Enanta Pharmaceuticals Inc shares while 36 reduced holdings. 23 funds opened positions while 49 raised stakes. 12.65 million shares or 0.84% less from 12.75 million shares in 2016Q3 were reported.
Acadian Asset Management Ltd, Massachusetts-based fund reported 568,686 shares. Assetmark holds 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) or 13 shares. Hays Advisory Limited Liability Company invested in 0.87% or 116,939 shares. Minnesota-based Ameriprise Fincl Inc has invested 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Northern Tru owns 190,311 shares for 0% of their portfolio. Dimensional Fund Advsr Ltd Partnership stated it has 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Weiss Multi invested in 20,000 shares. Thrivent Fincl For Lutherans, Minnesota-based fund reported 7,460 shares. Rhumbline Advisers holds 23,524 shares or 0% of its portfolio. Hanson Mcclain reported 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Loomis Sayles L P reported 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Moreover, United Serv Automobile Association has 0.01% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Mason Street Advsrs Limited Liability Co has invested 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Proshare Advsr Limited Liability Corp holds 0.01% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 15,393 shares. D E Shaw And reported 30,990 shares or 0% of all its holdings.

The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! The stock increased 4.55% or $1.96 on September 15, reaching $45.06. About 355,589 shares traded or 88.35% up from the average. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 40.91% since September 17, 2016 and is uptrending. It has outperformed by 24.21% the S&P500.
The move comes after 8 months positive chart setup for the $860.21 million company. It was reported on Sep, 17 by Barchart.com. We have $48.66 PT which if reached, will make NASDAQ:ENTA worth $68.82 million more.

Analysts expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report $1.94 EPS on November, 20.They anticipate $2.03 EPS change or 2,255.56 % from last quarter’s $-0.09 EPS. ENTA’s profit would be $37.04M giving it 5.81 P/E if the $1.94 EPS is correct. After having $-0.44 EPS previously, Enanta Pharmaceuticals Inc’s analysts see -540.91 % EPS growth.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Ratings Coverage

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Enanta Pharmaceuticals Inc had 14 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Mkt Outperform” rating on Friday, October 23 by JMP Securities. The firm earned “Market Outperform” rating on Tuesday, July 11 by JMP Securities. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) earned “Buy” rating by Zacks on Friday, August 7. On Saturday, August 8 the stock rating was downgraded by TheStreet to “Buy”. The rating was maintained by Robert W. Baird with “Neutral” on Tuesday, August 8. The stock has “Market Perform” rating by JMP Securities on Thursday, April 28. On Tuesday, August 9 the stock rating was maintained by JP Morgan with “Overweight”. The firm earned “Underweight” rating on Friday, October 23 by Barclays Capital.

More notable recent Enanta Pharmaceuticals Inc (NASDAQ:ENTA) news were published by: Seekingalpha.com which released: “Enanta: Half Cash, All Upside” on February 28, 2017, also Seekingalpha.com with their article: “Biotech Forum Daily Digest: Fallout From The ACA Repeal Debacle. Spotlight On …” published on March 27, 2017, Seekingalpha.com published: “Enanta Pharmaceuticals: Updates To Thesis” on August 06, 2017. More interesting news about Enanta Pharmaceuticals Inc (NASDAQ:ENTA) were released by: Businesswire.com and their article: “Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its …” published on September 13, 2017 as well as Seekingalpha.com‘s news article titled: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Fiscal Q3 2017 Results …” with publication date: August 08, 2017.

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The company has market cap of $860.21 million. The Firm uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. It currently has negative earnings. The Company’s research and development programs are focused on three disease targets: non-alcoholic steatohepatitis / primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.